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Abstract
Background: Pallido-ponto-nigral degeneration (PPND), a major subtype of frontotemporal dementia with parkinsonism
related to chromosome 17 (FTDP-17), is a progressive and terminal neurodegenerative disease caused by c.837 T > G
mutation in the MAPT gene encoding microtubule-associated protein tau (rs63750756; N279K). This MAPT mutation
induces alternative splicing of exon 10, resulting in a modification of microtubule-binding region of tau. Although
mutations in the MAPT gene have been linked to multiple tauopathies including Alzheimer’s disease, frontotemporal
dementia and progressive supranuclear palsy, knowledge regarding how tau N279K mutation causes PPND/FTDP-17 is
limited.
Results: We investigated the underlying disease mechanism associated with the N279K tau mutation using PPND/
FTDP-17 patient-derived induced pluripotent stem cells (iPSCs) and autopsy brains. In iPSC-derived neural stem
cells (NSCs), the N279K tau mutation induced an increased ratio of 4-repeat to 3-repeat tau and accumulation of
stress granules indicating elevated cellular stress. More significant, NSCs derived from patients with the N279K tau
mutation displayed impaired endocytic trafficking as evidenced by accumulation of endosomes and exosomes,
and a reduction of lysosomes. Since there were no significant differences in cellular stress and distribution of
subcellular organelles between control and N279K skin fibroblasts, N279K-related vesicle trafficking defects are
likely specific to the neuronal lineage. Consistently, the levels of intracellular/luminal vesicle and exosome marker
flotillin-1 were significantly increased in frontal and temporal cortices of PPND/FTDP-17 patients with the N279K
tau mutation, events that were not seen in the occipital cortex which is the most spared cortical region in the
patients.
Conclusion: Together, our results demonstrate that alterations of intracellular vesicle trafficking in NSCs/neurons
likely contribute to neurodegeneration as an important disease mechanism underlying the N279K tau mutation in
PPND/FTDP-17.
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Background
Frontotemporal dementia with parkinsonism related to
chromosome 17 (FTDP-17) prevails as one of the most
common form of early-onset dementia [1]. FTDP-17 pre-
sents as a fulminant progressive neurodegenerative de-
mentia, with no curative treatment or effective palliative
relief. Clinically, FTDP-17 displays a triad of symptoms,
with parkinsonism, behavioral changes and personality
dysfunctions, and later cognitive impairments [1, 2]. Two
genetic causes have been identified that lead to distinct
forms of FTDP-17; mutations in progranulin (GRN) cause
FTDP-17U (ubiquitin) with TDP-43 pathology and muta-
tions in the microtubule-associated protein tau (MAPT)
gene cause FTDP-17T (tau) [3]. Approximately one-half
of all FTDP-17 cases are caused by autosomal dominant
mutations in MAPT. The pallido-ponto-nigral degener-
ation (PPND) family is the largest and most comprehen-
sively studied kindred of tau N279K mutant carriers and
of all FTDP-17 families, containing to date, 59 affected in-
dividuals [4].
The N279K substitution is encoded within exon 10 of
theMAPT gene locus and is one of the most frequent mu-
tations in FTDP-17T patients [2]; together with muta-
tions P301L and intron 10 + 16. Together these three
mutations account for up to 60 % of FTDP-17T cases [5].
Multiple MAPT transcripts exist due to the alternative
splicing of the MAPT gene, and transcripts of MAPT can
be classified based on the inclusion/exclusion of exon 10
[6]. Most MAPT mutations including the N279K muta-
tion increase the transcript containing exon 10 resulting
in the overproduction of tau protein isoforms containing
four tandem microtubule-binding domain repeats (4R-
tau); whereas levels of the other major isoform in human
brain containing only three repeats (3R-tau) is believed to
be unaffected [7]. Although it is not fully understood how
the increase in 4R-tau contributes to disease pathogenesis,
MAPT mutations have been shown to cause multiple
tauopathies [8–10]. It is believed that tauopathies are
caused by aberrant hyperphosphorylation of tau, leading
to the assembly of variable neurotoxic tau aggregates and
deposition of insoluble tau fibers in both neurons and glia
[11]. Progressive tau deposition in FTDP-17T patients is
associated with severe neocortical atrophy of the frontal
and temporal lobes, in association with the degeneration
of medial temporal structures [12]. Destruction of the
basal ganglia and depigmentation of the substantia nigra
may also be present to some degree in MAPT mutant car-
riers, but are documented to be a consistent pathological
hallmark in N279K kindreds [13, 14].
The exact mechanism owing to the cell death of specific
neuronal populations in FTDP-17T remains to be identi-
fied; however, the characteristic dominant penetrance of
the N279K tau mutant suggests a gain-of-toxic-function
that results in specific subsets of degenerating cells. The
induced pluripotent stem cell (iPSC) technology provides
a novel and unparalleled approach to aid the study of mo-
lecular and cellular dynamics of disease pathogenesis by
utilizing patient-specific cells with pathologically linked
genetic mutations on the inherent genetic background
[15], which has facilitated its exponential use as a novel
tool to understand the pathogenesis of multiple neurode-
generative diseases [16]. Herein, we investigated the
pathogenic mechanism underlying FTDP-17T with mu-
tant N279K tau by using cells derived from two patients
from the PPND family who are both clinically affected.
Neural stem cells (NSCs) derived from the patient-specific
iPSCs revealed abnormal amounts of cellular vesicle com-
ponents in the presence of aberrantly spliced tau, accom-
panied by increases in several components of cellular
stress. Correspondingly, altered cellular markers reflecting
abnormal vesicle trafficking were observed in the autopsy
brains of patients carrying the N279K mutation, support-
ing the results from the iPSC-based approach. Our find-
ings demonstrate that patient-specific iPSCs can be used
to model neurodegenerative diseases and uncover cellular
dysfunctions associated with a disease-causing mutation.
Results
Generation and characterization of iPSCs
Two PPND family members known as N279K tau mutant
carriers were recruited into this study. Both were de-
scribed as clinically affected at the time of dermal extrac-
tion. Skin biopsy specimens were immediately processed
to generate primary fibroblasts. Commercially available
human dermal fibroblasts, documented to be clinically
normal, were used as a control. Genomic sequencing of
exon 10 of the MAPT locus confirmed the retention of
the c.837 T >G mutation (rs63750756; N279K) in fibro-
blasts from the PPND/FTDP-17T patients (Fig. 1a). The
fibroblasts were transfected with three episomal vectors
containing five transcription factors (OCT 3/4, SOX2, L-
MYC, KLF4, LIN28) and p53 shRNA for the conversion
to iPSCs, as previously described [17]. After 3-4 weeks of
the transfection, approximately 30 iPSC colonies per sub-
ject were selected and expanded. We first confirmed that
the iPSCs expressed several pluripotent stem cell specific
markers, including Nanog, TRA-1-81 and TRA-1-60 by
immunostaining (Fig. 1b). In addition, all iPSC lines could
spontaneously differentiate into cell types of all three germ
layers in vitro when they were stained for an endoderm
marker α-fetoprotein (AFP), a mesoderm marker α-
smooth muscle actin (SMA) and an ectoderm markers
Tuj1 (β III tubulin) and Nestin (Fig. 1c).
We examined mRNA expression of pluripotent markers
Oct3/4, Sox 2, Klf4, c-Myc, Nanog, REX, GDF3, FGF-4,
and ESG1 by RT-PCR in the iPSC lines. While skin fibro-
blasts expressed very low levels of these mRNAs except
Klf4 and c-Myc, all markers were up-regulated and/or
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Fig. 1 Generation and characterization of patient-specific iPSCs with N279K tau mutation. a Genomic DNA sequencing of the heterozygous MAPT
missense mutation c.837 T > G (p.N279K) in fibroblasts from the PPND/FTDP-17 patients. b Immunostaining of pluripotency markers (Nanog, TRA-
1-81 and TRA-1-60) in a control iPSC and two N279K iPSC lines. Scale bar, 50 μm. c In vitro differentiation of a control iPSC and two N279K iPSC
lines into cells of all three germ layers. Cells were immunostained for AFP (endoderm), SMA (mesoderm), Tuj1/Nestin (ectoderm), and DAPI (nucleus).
Scale bar, 50 μm. d-e Total mRNA levels of the reprogramming factors in a human ES cell line, a commercial iPSC line, a control iPSC line and
two N279K iPSC lines relative to the values in a control fibroblast were assessed by qRT-PCR. Data are mean ± SEM from three independent
experiments. f Phase-contrast images of the control iPSC line, embryonic bodies and neural rosettes. Immunostaining for the cells at different
stages of neuronal differentiation; Nestin and Pax6 for NSCs, Tuj1 for mature neurons, synaptophysin for presynapses, and DAPI. Scale bar, 50 μm
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induced in the iPSC lines, comparable to those of a hu-
man ES cell line (HUES2, Harvard Stem Cell Science) and
a validated iPSC line (ATCC ACS-1019) (Fig. 1d, e). These
results demonstrate the successful generation of patient-
specific iPSC lines with N279K mutation, which have
similar patterns of stem cell marker expression and the
pluripotency along with the control iPSC. To confirm the
differentiation methods of iPSC lines to neuronal linage,
the control iPSC line was further directed to form embry-
onic bodies and converted to the neural lineage through
the derivation of neurospheres to neural rosettes. Neural
rosettes were selected and dissociated to produce Nestin-
positive NSCs (Fig. 1f). NSCs derived from control iPSC
line could successfully differentiate to Tuj1-positive ma-
ture neurons, where a presynaptic marker synaptophysin
was also detected by immunostaining (Fig. 1f). However,
in the case of NSCs from iPSC lines with mutant tau
N279K, only a small percentage of NSCs differentiated
into mature neurons, suggesting the mutation significantly
affects neuronal survival. Those neurons from N279K
iPSC lines that did survive the differentiation process rap-
idly degenerated, preventing their use in studying cellular
functions. For these reasons, NSCs were used to study cel-
lular dysfunctions associated with the mutant N279K tau.
N279K tau mutation induces cellular stress in NSCs derived
from patient-specific iPSCs
To investigate potential effects of the N279K mutant tau
in NSCs, we differentiated control iPSC and the PPND/
FTDP-17T patient specific iPSC lines with N279K tau
mutation to produce Nestin-positive NSCs (Fig. 2a). As
expected, mRNA for human tau isoforms 3R-tau and 4R-
tau were shown to be differentially expressed in mutants
versus control NSCs. Levels of 3R-tau in N279K NSCs
were significantly lower than the control NSCs (Fig. 2b),
whereas 4R-tau mRNA levels were markedly increased in
Fig. 2 N279K neural stem cells exhibit altered tau isoform expression and enhanced cellular stress. a Immunostaining of NSC protein marker
Nestin in a control and the patient-derived NSCs with N279K tau mutant. b, c Quantitative RT-PCR analysis of 3R-tau and 4R-tau mRNAs in control and
N279K NSCs. Relative gene expression represents fold changes relative to that of control NSCs and normalized to β-actin expression. d Immunostaining of
stress granule markers G3BP and TIA-1 in control and N279K NSCs. e-h Western blot analysis of stress granule proteins G3BP and TIA-1 in control and
N279K NSCs. Quantification of Western blot densitometry of G3BP levels g and TIA-1 Levels h, normalized to GAPDH densitometry. i LDH quantification
normalized to Bradford protein levels. j Caspase 3/7 activity was measured in control and N279K NSCs and the quantification was normalized to Bradford
protein levels. Data are mean ± SEM from three independent experiments. *p< 0.05; **p< 0.01
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N279K NSCs (Fig. 2c). The mRNAs of both 3R-tau and
4R-tau were undetectable in the concomitant fibroblasts.
It has been recently reported that cellular stress induces
aggregation of RNA-binding proteins resulting in the for-
mation of inclusion bodies as stress granules [18], which
are implicated in several neurodegenerative diseases
including FTDP-17 [19]. Thus, we compared the qualita-
tive frequency of stress granule puncta in control and
N279K NSCs by immunostaining for G3BP and TIA-1.
Confocal microscopy showed that N279K NSCs display a
higher incidence of G3BP- or TIA-1-positive puncta than
in control NSCs (Fig. 2d). Similarly, protein expression
levels of G3BP (Fig. 2e, g) and TIA-1 (Fig. 2f, h) under
basal conditions were higher in N279K NSCs than control
NSCs when analyzed by Western blot. Consistent with
these results, we also found increased lactate dehydrogen-
ase (LDH) release into extracellular medium (Fig. 2i) and
increased capase-3/7 activity in living cells from the
N279K NSCs when compared to control NSCs (Fig. 2j).
There were no significant differences between control and
N279K skin fibroblasts in both LDH release (Fig. 4a) and
capase-3/7 activity (Fig. 4b), suggesting that N279K-
associated phenotypes are specific for the neuronal
lineage. Taken together, these results indicate that the
N279K tau mutation increases 4R-tau/3R-tau ratio and is
associated with induced cellular stress as early as at the
NSC stage.
Intracellular vesicle components are altered in the NSCs
with N279K tau mutation
The physiological function of tau is to stabilize microtu-
bules which are essential for proper intracellular traffick-
ing [20]. Thus, to further explore N279K-mediated defects
in NSCs, we probed for lipid raft marker Flotillin-1, which
is indicative of intermediate intracellular vesicles including
endosomes, multivesicular bodies and exosomes [21]
(Fig. 3a). Control NSCs demonstrated the inferred basal
expression of Flotillin-1, where the expression is sparse,
punctate are few and are mainly localized in nuclear re-
gions. Conversely, N279K NSCs displayed marked accu-
mulation of Flotillin-1 signal in the form of small nuclear
puncta and large vesicular puncta outside of the nuclear
region (Fig. 3a). In addition, N279K NSCs expressed higher
levels of the early endosome marker EEA1 observable as
discrete puncta surrounding the nucleus as well as dis-
played denser assemblage of EEA1-reactive puncta com-
pared to control NSCs (Fig. 3a). However, we found that
lower immunoreactivity of a lysosome marker LAMP-1 in
N279K NSCs than control NSCs. Correspondingly,
Western blot showed that protein levels of Flotillin-1
(Fig. 3b, c) and EEA1 (Fig. 3b, d) were significantly in-
creased in N279K NSCs than control NSCs. We also
found increased levels of the charged multivesicular
protein 2B (CHMP2B), which are indicative of higher
levels of endosomal compartments chaperoned and ma-
tured to the late endosome stage in N279K NSCs than
control NSCs (Fig. 3b, e). Consistent with the results
from confocal microscopy, Western blot analysis dem-
onstrated significantly depleted levels of LAMP-1 pro-
tein in N279K NSCs when compared to control NSCs
(Fig. 3b, f ). These results indicate that the N279K tau
mutation causes the enlargement of intraluminal vesicle
compartments including endosomes and exosomes, but
not that of lysosomes. We did not observe any signifi-
cant differences in immunostaining patterns (Fig. 4c)
and protein levels for these markers between control
and N279K skin fibroblasts (Fig. 4d-h), suggesting that
the vesicle trafficking defects are specific to the neur-
onal lineage.
Flotillin-1 levels are increased in the cortex of PPND/FTDP-17
patients with N279K tau mutation
To investigate whether our findings obtained using
patient-derived iPSCs occur in human brains, we analyzed
four postmortem brains from PPND family members who
were carriers of N279K tau mutation and affected by this
illness. The median age at death was 52 years and median
duration of illness was 6.6 years (Table 1). Neuronal loss
and superficial microvacuolation were present in the
frontal (Fig. 5a) and temporal cortices (Fig. 5b), but not
evident in the occipital cortex – the most spared cortical
region in PPND/FTDP-17 patients (Fig. 5c). The sections
stained with a phospho-tau antibody reveals numerous
tau-positive cell processes (“threads”), glia (astrocytes and
oligodendroglial “coiled bodies”), and pre-tangles, in
frontal (Fig. 5d) and temporal cortex (Fig. 5e), but only
rare threads and coiled bodies in occipital cortex (Fig. 5f).
αB-crystallin-positive balloon neurons and coiled bodies
were found in frontal (Fig. 5g) and temporal cortex
(Fig. 5h), but only rare labelling of glia were found in oc-
cipital cortex (Fig. 5i).
We found that Flotillin-1 protein levels were signifi-
cantly increased in the frontal (Fig. 5j) and temporal cor-
tex (Fig. 5k) of PPND/FTDP-17 patients with N279K tau
mutation compared to control individuals, which is con-
sistent with our results from the iPSC-based analysis. In
occipital cortex, no significant change was detected in
Flotillin-1 levels between control individuals and the pa-
tients (Fig. 5l). Increased CHMP2B levels were also ob-
served in the frontal cortex, but not in temporal and
occipital cortices (Fig. 6a-f). In addition, there were no sig-
nificant differences in EEA1 and LAMP1 levels in frontal,
temporal and occipital cortex between and control and
the N279K carriers (Fig. 6a-f ). We also confirmed the up-
regulation of 4R-tau mRNA levels in the cortex of these
patients (Fig. 6g). Thus, these results indicate that NSCs
derived from the patient-specific iPSCs model neuronal
phenotypes of PPND/FTDP-17 patients with N279K tau
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mutation, where disturbances of intracellular vesicle traf-
ficking in neuronal cells may contribute to the patho-
logical changes.
Discussion
Inheritance of one allele of MAPT with the N279K muta-
tion is causal to the development of pre-geriatric demen-
tia, in the form of FTDP-17 [14]. The mutation resides
within an exonic splicing enhancer site, and increases the
level of the isoform containing exon 10, resulting in
enhanced 4R-tau mRNA production [22]. Whereas 4R-tau
protein is shown to have a stronger interaction with mi-
crotubules than 3R-tau, 4R-tau is also more effective at
assembling microtubules [23]; the N279K mutation does
not appear to affect the binding of tau to microtubules or
decrease the ability of tau to promote microtubule assem-
bly when compared to wild-type 4R-tau [24]. Thus, it re-
mains unclear how the N279K tau mutant leads to
neurodegeneration and tauopathy in FTDP-17T patients.
In this study, we demonstrate that NSCs carrying the
Fig. 3 N279K tau mutant alters intracellular vesicle markers and their distributions in NSCs. a Immunostaining of Flotillin-1, EEA1 and LAMP-1 in control
and N279K NSCs. b-f Western blot analysis of Flotillin-1, CHMP2B, EEA1 and LAMP-1 in control and N279K NSCs. Quantification of Western blot
densitometry of Flotillin-1 c, EEA1 d, CHMP2B e and LAMP-1 levels f. Data are mean ± SEM from three independent experiments. *p < 0.05; **p < 0.01
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N279K tau mutant exhibit higher levels of 4R-tau and
markedly higher cellular stress compared with control
NSCs using patient-specific iPSCs. Furthermore, we show
that intracellular vesicle trafficking is significantly per-
turbed. Importantly, we show that N279K tau influences
intracellular vesicle trafficking as early as the NSC stage,
which could not be examined through previous in vitro
experiments.
Endocytosed and intracellular products are packaged into
membrane bound specialized vesicles that are trafficked
along microtubules to reach their correct destination or
perform their specialized function to ensure proper cell
dynamics. Impairment in the orderly trafficking of proteins
and lipids intracellularly has been documented to initiate
and execute cell death processes. Furthermore, intra-
organelle communication is also believed to play a crucial
role in the initiation of cell death events [25]. Mounting evi-
dence implicates trafficking alterations, in particular, de-
regulation of the endosomal system in the pathogenesis of
neurodegenerative diseases [26]. In this work, we find sub-
stantial increases in the levels of flotillin-1 in N279K NSCs.
Flotillin proteins which represent scaffolds of lipid raft mi-
crodomains [21] are involved in the sorting of intracellular
vesicle compartments toward Golgi apparatus, recycling
Fig. 4 N279K fibroblasts do not display alterations in cellular stress or markers of vesicle trafficking. a LDH secretion was measured in control and
N279K fibroblasts. The quantification was normalized to Bradford protein levels of cell lysate. b Caspase 3/7 activity was measured in control and
N279K fibroblasts. The quantification was normalized to Bradford protein levels of cell lysate. c Immunostaining of control and N279K fibroblasts,
demonstrating EEA1, Flotillin-1 and LAMP-1 positive punctates. d-h Expression levels of EEA1 e, CHMP2B f, Flotillin-1 g and LAMP-1 h in control
and N279K fibroblasts were analyzed by Western blot. Data are mean ± SEM from three independent experiments. N.S., Not Significant
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endosomes, multivesicular bodies [27], late endosomes/ly-
sosomes [28] and exosomes [29]. Thus, the accumulation
of flotillin-1 in intracellular space is indicative of interrup-
tions of proper vesicle trafficking or abnormal acceleration
of endocytosis machinery. Furthermore, our results show
markedly increased levels of an early endosome marker
EEA1 and a late endosome marker CHMP2B in N279K
NSCs. In contrast, N279K NSCs show marked depletion of
lysosomal compartments and protein levels of lysosomal
marker LAMP-1. Lysosomes are highly dynamic membrane
bound organelles whose main role is to receive and termin-
ally degrade components sequentially sent through the
endocytic pathway and from autophagic processes [30].
Therefore, the possession of the tau N279K mutant may
disrupt the delivery of waste products from endosomes to
lysosomes in NSCs, resulting in enlarged intracellular vesi-
cles such as endosomes and exosomes. The aberrant pro-
cessing of intracellular vesicles eventually render NSCs
more intrinsically vulnerable to internal stressors and initi-
ate signaling of cell stress through their accumulation. This
accumulation may saturate the endocytic pathway and lead
to the theorized propagation of pathologic/harmful prod-
ucts through intercellular exosomal transfer. Whilst this is
seen as a permissive and protective mechanism to relieve
intracellular vesicular traffic, exosomal enrichment of
pathogenic tau may be speculated as an underlying vector
of disease spread in FTDP-17.
Consistent with our NSC data, we show the increased
flotillin-1 in the frontal and temporal cortices in post-
mortem brain tissue of N279K carriers, and increased
CHMP2B levels in the frontal cortex of the PPND/FTDP-
17 patients. Interestingly, mutations in CHMP2B are also
causal for the development of FTD [31, 32] and amyo-
trophic lateral sclerosis [33]. CHMP2B is a subunit of
endosomal sorting complex required for transport-III,
which is involved in the degradation of proteins in the
endocytic and autophagic pathways [34]. In fact, CHMP2B
immunoreactive granules are observed as granulovacuolar
degeneration in the brains of Parkinson’s disease, inciden-
tal Lewy body disease [35] and Alzheimer’s disease (AD)
patients [36]. Flotillin-1 is also known to accumulate in
tangle-bearing neurons in AD brains [37]. Thus, the alter-
ation of vesicle trafficking is likely a common pathogenic
event across a spectrum of neurodegenerative diseases,
although further work is required to completely elucidate
whether the trafficking disturbance is a cause or a conse-
quence of neurodegeneration.
In FTDP-17T as well as other neurodegenerative dis-
eases termed tauopathies, accumulation of tau path-
ology is the primary histological feature. Flotillin-1 is
increased in the frontal and temporal cortex, but not in
occipital cortex where tau accumulation and deposition
is relatively mild. Since 4R-tau levels are increased in
all three cortical regions from the patients, there might
be specific molecular mechanisms to compensate for
the harmful effects of increased 4R-tau due to N279K
tau in occipital cortex. Mutant N279K tau may initiate
or facilitate the aggregation of tau into filaments by af-
fecting vesicle trafficking in NSCs and/or neurons later
on in disease when compensatory mechanisms are
expended. Exosomes provide a motile intercellular
chamber for the delivery of endocytosed and intracellu-
lar molecules to the extracellular space, for the active
uptake by neighboring cells, which has been recently
hypothesized to be a major component in the phenom-
ena of disease pathology propagation [38], especially in-
volving tau [39]. Since flotillin-1 is abundantly localized
and enriched in intraluminal vesicles/exosomes, it is
possible that N279K tau mutation facilitates the forma-
tion of exosomes and potentiates the spreading of tau
pathology, which exacerbates cellular viability later on
in the course of the disease.
Table 1 Postmortem brain samples from PPND/FTDP-17 patients with N279K tau mutation
Age of Onset Disease Duration Age at Death Gender Race Pathological Diagnosis Mutation
- - 61 Female Caucasian Normal -
- - 54 Female Caucasian Normal -
- - 56 Female Caucasian Normal -
- - 57 Female Caucasian Normal -
44 6.5 50 Female Caucasian PPND/ MAPT
FTDP-17 c.837 T > G (p.N279K)
43 8.0 51 Female Caucasian PPND/ MAPT
FTDP-17 c.837 T > G (p.N279K)
48 4.8 53 Female Caucasian PPND/ MAPT
FTDP-17 c.837 T > G (p.N279K)
46 6.8 53 Female Caucasian PPND/ MAPT
FTDP-17 c.837 T > G (p.N279K)
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Conclusions
Our results show that NSCs harboring the mutant
N279K tau display altered levels of multiple intracellular
vesicle trafficking markers, suggesting disruptions in the
transport of membrane-bound organelles, which may ul-
timately lead to enhanced cellular stress observed in tau
mutant cells. These findings have important implications
for our understanding in the pathogenic mechanism of
N279K tau mutation and those findings might be partly
shared with sporadic FTD and/or PSP. Further studies
are needed to elucidate the precise pathways by which
N279K mutant tau alters intracellular vesicle trafficking.
Fig. 5 Histopathologic findings and Western blot analysis of cortex in autopsy-confirmed PPND/FTDP-17 patients with N279K tau mutant. a Neuronal
loss and superficial microvacuolation demonstrated by H & E staining in the frontal and b temporal cortex, but c occipital cortex is relatively spared in
PPND/FTDP-17 patients. Scale bar, 100 μm. d Phospho-tau-positive pre-tangles, threads, and coiled bodies in frontal cortex and e temporal cortex but,
f only rare threads and glia are found in occipital cortex of PPND/FTDP-17 patients. Scale bar, 25 μm. g Ballooned neurons detected by αB-crystallin
staining are found in the frontal and h temporal cortex, but i only rare αB-crystallin-positive glia are found in occipital cortex from PPND/
FTDP-17 patients. Scale bar, 25 μm. j-l Western blot analysis of Flotillin-1 levels in the frontal j, temporal k and occipital l cortex from control
non-demented controls (n = 4) and PPND/FTDP-17 patients (n = 4). Data are mean ± SEM. *p < 0.05
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Importantly, our findings provide evidence that iPSC
technology can be used to successfully model early dys-
functions in somatic cells derived from affected human
patients, which can be complemented by post-mortem
brain studies and may underlie future advances in the
translatability of research involving PPND/FTDP-17
patients.
Methods
Isolation of primary human skin fibroblasts and generation
of iPSCs
Studies were approved by Mayo Clinic under IRB proto-
cols (09-003803 and 12-002562). Clinically affected two
patients from PPND family were recruited; #1) 48 year-old
patient (male, Caucasian) with the disease onset at
44 year-old and #2) 50 year-old patient (female, Cauca-
sian) with the disease onset at 49 year-old. After informed
consent was obtained, dermal skin biopsy specimens were
harvested in a routine fashion from the medical aspect of
non-dominant fore arm. The patients were clinically gen-
etically tested to confirm N279K tau mutation status.
DNA was extracted from the fibroblasts with standard
protocol and Sanger sequencing for the c.837 T >G muta-
tion (p.N279K) in exon 10 of the MAPT on chromosome
17 was performed using the primer pair 10 F (5’-TGC
CTC TGC CAA GTC CGA AAG-3’) and 10R (5’-CCA
GAT CCT GAG AGC CCA AGA AG-3’). Control fibro-
blasts were obtained from Cell Applications, Inc. (Catalog
No. 106-5a; Lot No. 2023). Fibroblasts were amplified and
maintained in fibroblast medium; DMEM culture medium
(Invitrogen) containing 10 % fetal bovine serum (FBS)
(Gemini Bio-Products), and supplemented with 1 % non-
essential amino acids (NEAA) (Invitrogen), 1 % Penicillin-
Streptomycin (Invitrogen), and 1 % Amphotecerin B
(Gemini Bio-Products). The iPSCs were created by the
electroporation of three episomal vectors containing,
OCT3/4, SOX2, KLF4, L-MYC, LIN28, and p53-shRNA
(Addgene), as described before [17], transfection was
assisted with the NHDF nucleofection kit (Lonza). Cells
were plated on a 35 mm dish in fibroblast medium, 24 h
later, a 100 % media change was performed. Seven days
after nucleofection, cells were trypsinzed (0.25 % trypsin/
1 mM EDTA, Gibco) and re-plated onto a MEF feeder
layer (Global Stem) in a 100 mm dish in fibroblast
medium. After 24 h, medium was replaced with mTeSR1
complete medium (STEMCELL Technologies) and was
changed every day. The iPSC colonies were isolated and
expanded approximately after 3-4 weeks in culture. The
iPSC colonies were passaged using dispase (STEMCELL
Technologies) and subject to treatment with rock inhibi-
tor Y27632 (Sigma-Aldrich).
Differentiation of iPSCs
Embryonic bodies were produced after treating iPSC col-
onies with dispase and placing them in human neural
stem cell differentiate medium (50 % DMEM/F12 plus
50 % Neural basal medium (Gibco) containing 1 % N2
supplement (Gibco), 2 % B27 supplement (Gibco), 1 μM
Dorsomorphin (Sigma-Aldrich), 10 μM SB431542 (Sigma-
Aldrich)) in a 100 mm petri dish. Medium was changed
every two days. After 2 weeks, spheres were seeded on
polyornithine (Sigma-Aldrich) and laminin (Sigma-Aldrich)
coated dishes and kept culturing in the same medium for
another 7-14 days for neural rosette formation. Neural
Fig. 6 Subcellular vesicle components and tau mRNA levels in the cortices of PPND/FTDP-17 patients with N279K tau mutation. a-f Western blot analysis
of EEA1, CHMP2B and LAMP-1 levels in the frontal a, b, temporal c, d and occipital e, f cortex from non-demented controls (n = 4) and PPND/
FTDP-17 patients (n = 4). g Quantitative RT-PCR for levels of 3R-tau and 4R-tau mRNA in the frontal, temporal and occipital cortex from control
non-demented controls (n = 4) and PPND/FTDP-17 patients (n = 4). Relative gene expression represents fold changes relative to control patient
levels, normalized to β-actin. Data are mean ± SEM. *p < 0.05. N.S, Not Significant
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rosettes were collected with Stem Diff neural rosette selec-
tion reagent and re-plated onto polyornithine/laminin
coated dishes as a single cell suspension in neural stem
cell culture medium (ReNcell NSC maintenance media
(Millipore) containing, 1 % N2 supplement, 1 % NEAA,
20 ng/ml bFGF and 20 ng/ml EGF). For three germ layers
differentiation, iPSC colonies were digested with dispase
and culture in DMEM with 10 % FBS for 4 days in 10 cm
petri dish. After 4 days in suspension culture, floating em-
bryonic bodies were re-seeded onto gelatin-coated dishes
in the same culture medium for 10 days. The medium was
changed every other day.
Immunocytochemistry
Cells were passaged on 4 well slides (Lab-Tek 0.1 borosili-
cate glass slides) at 37 °C before experiments. Once iPSC
colonies grew large enough or reached final differentiation
stage, cells were briefly fixed in 4 % paraformaldehyde and
then permeabilized in 0.2 % Triton X-100 in PBS. Cells
were blocked with 10 % normal goat serum for 30 min,
before incubation with primary antibody for 1 h at room
temperature. Cells were incubated with primary antibodies
against Nanog (Cell Signaling), TRA-1-60 (Chemicon
International), TRA-1-81 (Chemicon International), AFP
(R & D Systems), SMA (Abcam), Tuj1 (Covance), Synap-
tophysin (Millipore), Pax6 (Abcam), Nestin (Abcam),
Flotillin-1 (Novus Biologicals), Lamp1 (Santa-Cruz), G3BP
(BD Biosciences), TIA-1 (Santa-Cruz) or EEA1 (BD
Transduction Laboratories). After washing with PBS, cells
were incubated with Alexa Fluor-488 or 568 conjugated
secondary antibodies for 1 h at room temperature. Fluor-
escent signals were detected by fluorescence microscopy
(model IX71 Invert, Olympus) or confocal laser scanning
fluorescent microscopy (model LSM510 Invert, Carl Zeiss)
and images were processed using Photoshop.
RNA extraction and RT-PCR
Total cellular RNA was extracted from cells using RNeasy
mini kit (Qiagen), according to the manufacturer’s instruc-
tions, and subject to DNase 1 digestion to remove con-
taminating genomic DNA. Total RNA was dissolved in
nuclease-free water and reverse transcribed using the
Superscript III First-Strand synthesis System (Invitrogen).
The cDNA from the reaction mix was subject to quantita-
tive real-time PCR to detect levels of each corresponding
gene. The set of actin primers was used as an internal con-
trol for each specific gene amplification. The relative levels
of gene expression were quantified through use of the
Bio-Rad iCycler iQ software. The primers used to amplify
target genes by RT-PCR and quantitative PCR were as fol-
lows; endogenous hOCT3/4 F (5’-GAC AGG GGG AGG
GGA GGA GCT AGG-3’) and R (5’-CTT CCC TCC
AAC CAG TTG CCC CAA AC-3’), endogenous hSOX2 F
(5’-GGG AAA TGG GAG GGG TGC AAA AGA GG-3’)
and R (5’-TTG CGT GAG TGT GGA TGG GAT TGG
TG-3’), endogenous hKLF4 F (5’-ACG ATC GTG GCC
CCG GAA AAG GAC C-3’) and R (5’-TGA TTG TAG
TGC TTT CTG GCT GGG CTC C-3’), endogenous hc-
MYC F (5’-GCG TCC TGG GAA GGG AGA TCC GGA
GC-3’) and R (5’-TTG AGG GGC ATC GTC GCG GGA
GGC TG CAG-3’), GDF3 F (5’-CTT ATG CTA CGT
AAA GGA GCT GGG-3’) and R (5’-GTG CCA ACC
CAG GTC CCG GAA GTT-3’), REX1 F (5’-CAG ATC
CTA AAC AGC TCG CAG AAT-3’) and R (5’-GCG TAC
GCA AAT TAA AGT CCA GA-3’), NANOG F (5’-CCC
CGA TTC TTC CAC CAG TCC C-3’) and R (5’-CGG
AAG ATT CCC AGT CGG GTT CAC C-3’), FGF4 F (5’-
CTA CAA CGC CTA CGA GTC CTA CA-3’) and R (5’-
GTT GCA CCA GAA AAG TCA GAG TTG-3’), ESG1 F
(5’-ATA TCC CGC CGT GGG TGA AAG TTC-3’) and R
(5’-ACT CAG CCA TGG ACT GGA GCA TCC-3’), 3R-
tau F (5’-TTG CTC AGG TCA ACT GGT TTG TA-3’)
and R (5’-ACT GAG AAC CTG AAG CAC CA-3’), 4R-
tau F (5’-GAA GCT GGA TCT TAG CAA CG-3’) and R
(5’-TTA CTT CCA CCT GGC CAC CTC CT-3’), β-actin
F (5’-CTG GCA CCA CAC CTT CTA CAA TG-3’) and R
(5’-AAT GTC ACG CAC GAT TTC CCG C-3’).
Cell toxicity assays
Caspase 3/7 activity was assessed using a Caspase-Glo 3/7
assay (Promega) according to the manufacturer’s direc-
tions. Background readings were subtracted from the
measured luminescence value and positive controls were
present in each assay and cell type using 0.5 μM of staur-
osporine treatment for 18 h, to ensure signal validity.
LDH concentration was measured in cell culture super-
natant that had been pre-incubated on confluent cells for
24 h, and was detected using the LDH activity assay kit
(Sigma), according to manufacturer’s instructions.
Western blotting
Cells were lysed in 1 % Triton X-100 PBS containing 1 %
protease inhibitor cocktail (Roche), triturated and centri-
fuged at 13,000 g for 10 min at 4 °C. Brain lysates were
prepared from frozen brain tissue using a one-step extrac-
tion method, where 100 mg of tissue was lysed in ice-cold
1 % Triton X-100 PBS containing 1 % protease inhibitor
cocktail and centrifuged at 100,000 g for 15 min at 4 °C.
Samples were separated on 10 % SDS-polyacrylamide gels
and transferred to PVDF Immobilon FL membranes
(Millipore) overnight. Membranes were blotted with pri-
mary antibodies against Flotillin-1 (Novus Biologicals),
Lamp-1 (Santa-Cruz), G3BP (BD Biosciences), TIA-1
(Santa-Cruz), EEA1 (BD Transduction Laboratories) or
CHMP2B (Abcam) in 5 % non-fat milk containing 0.01 %
Tween-20. Odyssey IR680 or IR800 secondary antibodies
against the species of the primary antibody were incubated
for 1 h at room temperature. Immunoreactive bands were
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detected and quantified using the odyssey infrared im-
aging system (LI-COR Biosciences).
Human brain sample analysis
Postmortem tissues were obtained through the Mayo
Clinic Jacksonville brain bank for neurodegenerative dis-
eases. All brains were donated from affected PPND family
members who were clinically genetically confirmed to be
N279K tau mutation carriers. Demographic characteristics
are shown in Table 1. A standardized detailed neuropatho-
logic assessment included routine histological examination
with hematoxylin & eosin (H & E) staining as well as im-
munostaining with a phospho-tau monoclonal antibody
phospho-tau antibody (CP13, mouse IgG1, 1:1,000, kind
gift of Peter Davies, Feinstein Institute for Medical
Research, North Shore LIJ Health Care System) and αB-
crystallin (Rabbit polyclonal, 1/5,000 dilution; Chemicon,
Temecula, CA).
Statistical analysis
All quantified data represents an average of samples. Stat-
istical significance was determined by two-tailed paired
student’s t test, and p < 0.05 was considered significant.
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